Valproate Sodium (Page 10 of 10)

17 PATIENT COUNSELING INFORMATION

Hepatotoxicity

Warn patients and guardians that nausea, vomiting, abdominal pain, anorexia, diarrhea, asthenia, and/or jaundice can be symptoms of hepatotoxicity and, therefore, require further medical evaluation promptly [see Warnings and Precautions ( 5.1)] .

Pancreatitis

Warn patients and guardians that abdominal pain, nausea, vomiting, and/or anorexia can be symptoms of pancreatitis and, therefore, require further medical evaluation promptly [see Warnings and Precautions ( 5.5)] .

Birth Defects and Decreased IQ

Inform pregnant women and women of childbearing potential that use of valproate during pregnancy increases the risk of birth defects and decreased IQ in children who were exposed. Advise women to use effective contraception while using valproate. When appropriate, counsel these patients about alternative therapeutic options. This is particularly important when valproate use is considered for a condition not usually associated with permanent injury or death [see Warnings and Precautions ( 5.2, 5.3, 5.4) and Use in Specific Populations ( 8.1)] .

Advise women of childbearing potential to discuss pregnancy planning with their doctor and to contact their doctor immediately if they think they are pregnant.

Hyperammonemia

Inform patients of the signs and symptoms associated with hyperammonemic encephalopathy and notify to inform the prescriber if any of these symptoms occur [see Warnings and Precautions ( 5.8, 5.9)] .

CNS Depression

Since valproate products may produce CNS depression, especially when combined with another CNS depressant (e.g., alcohol), advise patients not to engage in hazardous activities, such as driving an automobile or operating dangerous machinery, until it is known that they do not become drowsy from the drug.

Multiorgan Hypersensitivity Reactions

Instruct patients that a fever associated with other organ system involvement (rash, lymphadenopathy, etc.) may be drug-related and should be reported to the physician immediately [see Warnings and Precautions ( 5.11)] .

Manufactured by:
Fresenius Kabi
Lake Zurich, IL 60047

www.fresenius-kabi.com/us

451466A

Revised: May 2019

image 4image 4

PACKAGE LABEL — PRINCIPAL DISPLAY PANEL — Valproate Sodium 5 mL SIngle Dose Vial Label

NDC 63323-494-41


Valproate Sodium Injection, USP

500 mg* per 5 mL

(100 mg per mL)

For intravenous infusion only.
Preservative free.

5 mL Single-dose Vial Rx only

Vial label
(click image for full-size original)

PACKAGE LABEL — PRINCIPAL DISPLAY PANEL — Valproate Sodium 5 mL Single Dose Vial Tray Label

NDC 63323-494-16


Valproate Sodium Injection, USP

500 mg* per 5 mL

(100 mg per mL)

For intravenous infusion only.
Preservative free.

10 x 5 mL
Single-dose Vials Rx only

vial tray labelVial labelvial tray label
VALPROATE SODIUM
valproate sodium injection, solution
Product Information
Product Type HUMAN PRESCRIPTION DRUG Item Code (Source) NDC:63323-494
Route of Administration INTRAVENOUS DEA Schedule
Active Ingredient/Active Moiety
Ingredient Name Basis of Strength Strength
VALPROATE SODIUM (VALPROIC ACID) VALPROIC ACID 100 mg in 1 mL
Inactive Ingredients
Ingredient Name Strength
EDETATE DISODIUM 0.4 mg in 1 mL
SODIUM HYDROXIDE
HYDROCHLORIC ACID
Packaging
# Item Code Package Description Multilevel Packaging
1 NDC:63323-494-16 10 VIAL, SINGLE-DOSE in 1 TRAY contains a VIAL, SINGLE-DOSE (63323-494-41)
1 NDC:63323-494-41 5 mL in 1 VIAL, SINGLE-DOSE This package is contained within the TRAY (63323-494-16)
Marketing Information
Marketing Category Application Number or Monograph Citation Marketing Start Date Marketing End Date
ANDA ANDA076539 08/18/2003
Labeler — Fresenius Kabi USA, LLC (608775388)
Establishment
Name Address ID/FEI Operations
Fresenius Kabi USA, LLC 840771732 manufacture (63323-494)

Revised: 05/2019 Fresenius Kabi USA, LLC

All MedLibrary.org resources are included in as near-original form as possible, meaning that the information from the original provider has been rendered here with only typographical or stylistic modifications and not with any substantive alterations of content, meaning or intent.

This site is provided for educational and informational purposes only, in accordance with our Terms of Use, and is not intended as a substitute for the advice of a medical doctor, nurse, nurse practitioner or other qualified health professional.

Privacy Policy | Copyright © 2021. All Rights Reserved.